Status:
NOT_YET_RECRUITING
Perfusion Abnormalities in Hypertrophic Cardiomyopathy
Lead Sponsor:
University of Virginia
Conditions:
Hypertrophic Cardiomyopathy (HCM)
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to investigate whether myocardial microvascular perfusion in patients with hypertrophic cardiomyopathy improved after initiation of cardiac myosin inhibitor therapy.
Eligibility Criteria
Inclusion
- Diagnosis of hypertrophic cardiomyopathy
- Subject being initiated on clinically-indicated cardiac myosin inhibitor therapy
Exclusion
- Pregnancy
- Lactation
- Allergy to ultrasound enhancing agent (lipid-stabilized) or regadenoson
- Serious AE to regadenoson
- Hypotension
- Serious bradycardia not addressed by pacemaker
- Moderate or greater reactive airways disease
Key Trial Info
Start Date :
November 15 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2028
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06599229
Start Date
November 15 2024
End Date
December 1 2028
Last Update
September 19 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.